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conducted with 9 FM-association counsellors in 3 countries,
analysed using the same method and used to enrich the model.
Further information was captured with the analysis of 90 letters
written by patients to FM-associations. RESULTS: A total of 303
abstracts were retrieved and reviewed. Sixty-seven publications
were included and the concepts identiﬁed were grouped into the
following domains: Burden, Symptoms and Inﬂuencing Factors.
The exploratory interviews suggested that burden can be divided
into: Autonomy, Coping, Pain, Tiredness, Activities of Daily
Living, Physical Impact, Social Impact, Psychological Impact,
Cognitive Impact, Work, Sleep, Relationship to Medicine and
Disease. The letters and counsellor interviews conﬁrmed the con-
ceptual content. CONCLUSIONS: The resulting model illus-
trates how “burden” is understood by FM patients, and that all
areas of daily life are impacted by the disease. The conceptual
content will be used for the generation of items for the question-
naire. The development of a questionnaire assessing functional
impact and burden will allow the consequences of FM on
patients to be more widely recognised.
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OBJECTIVES: Background: Minor injury is a leading cause of
PED visits and a major health care burden. However, little is
known about outcomes after treatment and release; care often
lacks an evidence base. OBJECTIVES: 1) Gather initial data on
the clinical/functional outcomes after PED care, and 2) Test
both patient and proxy forms of an acute HRQOL tool in the
PED and in telephone follow-up. METHODS: Prospective con-
venience sample of pediatric patients treated for injury and dis-
charged to home. Demographic and injury data collected at the
visit; outcomes by telephone at 7–10 days. The acute Pediatric
Quality of Life Inventory 4.0 (PedsQL) was administered at
both visit and follow-up. RESULTS: Thirty-ﬁve families com-
pleted follow-up. Mean patient age = 8 years, 69% male, 49%
soft tissue injury, 31% fracture, 17% sprains, 3% CHI. Types/
locations of study injuries were in frequencies similar to those
in our ED overall. Children had a median of 3 days of pain;
24% reported 37 after the visit. Days for the child’s return to
normal activity: median 3, 37% 37. Disruption of normal
family activities in 51%, for a median of 5 days, 39% 37. Chil-
dren with school, work, or other regularly scheduled activities:
55% missed 33 days, 20% missed 37. Parents missed work or
school: mean 1 day, 22% 33. The PedsQL was found to be easy
to use, had minimal missing items, and good indication con-
struct validity (total scores inversely correlating to days of pain,
abnormal activities, and family disruption). CONCLUSIONS:
We found signiﬁcant morbidity for patients and their families
after PED visits for minor injury. In this setting, the use of the
acute PedsQL patient/proxy forms was feasible with initial indi-
cations of good construct validity. Further description and the
development/testing of a tool to quantify short-term outcomes
are prerequisites to testing effectiveness in ED minor injury
care.
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BACKGROUND: Anti-TNF therapies are efﬁcacious in clinical
trials for the treatment of RA.However, their long-term efﬁcacy in
daily practice in relation to the speciﬁc diagnosis or the use of
concomitant DMARD therapy remains to be conﬁrmed. OBJEC-
TIVES: To estimate the proportion of patients with RA, treated
with at least one anti-TNF therapy (inﬂiximab [IFX], etanercept
[ETN], or adalimumab [ADA]), who were still on the same
biologic agent after 3 yrs (36 mths) of follow-up. To estimate the
discontinuation rate of patients with RA, treated with the second
anti-TNF therapy, after discontinuing the ﬁrst one. METHODS:
Patients attending participating centers who received their ﬁrst
anti-TNF treatment between July 1, 2002 and March 31, 2004,
and who gave their consent, were invited to participate to the
study. Pts were required to be18 yrs old, with a diagnosis of RA
(as deﬁned by the ACR criteria). A total of 711 patients were
enrolled in this retrospective cohort study involving a national
representative sample of 23 rheumatology centers in Italy, selected
according to both geography and treatment setting characteristics.
A patient chart review was conducted to collect data on treatment
duration, and a diary of therapies was completed. A Kaplan–
Meier curve was calculated for each biologic anti-TNF therapy;
the event was discontinuation of the drug due to inefﬁcacy or
toxicity. RESULTS: Pts’ baseline characteristics were: female
80.8%, mean age 53.3 yrs (range 18–84 yrs), mean duration of
disease 9.4 yrs. Of 703 pts who met the inclusion criteria, 248
(35.3%) were treated with IFX, 259 (36.8%) with ETN and 196
(27.9%) with ADA. After a follow-up of 36 months, the discon-
tinuation rate was 43.2% with IFX, 25.8% with ETN and 28.0%
with ADA. The discontinuation rate of IFX compared with ETN
and ADA was statistically higher (p = 0.0001 and p = 0.0002,
respectively). The difference between ADA and ETN was not
statistically signiﬁcant (p = 0.826). Patients who discontinued the
ﬁrst agent and started the second onewere 149: ETN112, INF 12,
ADA 25. After 24 months of follow up 78% patients on ETN,
46% on ADA and 25% on INF were still on the same agent. The
RR of stopping the second agent increased by 31% (IC 95%
0.96–1.83). CONCLUSIONS: Our results show a higher discon-
tinuation rate of anti-TNF therapies in daily practice in Italy
compared with clinical trials. IFX was associated with a signiﬁ-
cantly higher rate of drug discontinuation than other anti-TNFs.
Patients who stopped the ﬁrst agent and switched to the second
one had a discontinuation risk increase of of 31%. This results
should be taken into account when ﬁrst agent fails.
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OBJECTIVES: To determine surgical treatment outcomes in
patients with cartilage defects according to operative procedures
performed. METHODS: In this 5-year retrospective cross-
sectional study patients were contacted who had been diagnosed
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with and, if necessary, treated for knee cartilage defects by
arthroscopy at one of seven centres in Germany. Patients were
assigned to the initial operation (IO) group if the study physician
was able to conﬁrm that the study arthroscopy was the patient’s
ﬁrst surgical procedure ever on that particular knee. All other
patients were assigned to the re-operation (RO) group. Patients
were interviewed on their postsurgical outcome with two disease-
speciﬁc (Tegner Scale and IKDC Subjective Knee Form [IKDC-
SKF] including a retrospective assessment of their pre-surgical
health state) and a generic instrument (SF-36). RESULTS: Data
from a total of 1708 patients were included in the ﬁnal analysis.
Of these, 1070 were assigned to the initial operation (IO) group
(61% men, 49  15 years; 39% women, 52  14 years) and 638
were assigned to the re-operation (RO) group (64% men,
44  13 years; 36% women, 47  14 years). Participants expe-
rienced a level reduction of 1.5 (IO) and 2.5 (RO) resp. with the
Tegner scale. Patients reported a functional knee status measured
by the IKDC-SKF of 64% to 84% dependent on the surgical
procedure performed. Signiﬁcantly lower scores than the general
population were observed with the SF-36 for the physical func-
tioning, role-physical, and role-emotional scales, as well as for
the physical health summary measure. The strongest limitations
in the overall study population compared to the general popula-
tion were seen on the physical functioning, role-physical, and
role-emotional dimensions. In all three instruments the RO
group experienced more severe reductions in quality of life.
CONCLUSIONS: Despite extensive treatments participants
experienced lasting reductions in quality of life. Surgical proce-
dures differ in their long-term outcome. Longer history of inter-
ventions decrease the treatment related outcomes.
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OBJECTIVES: Total hip and knee replacement are very common
procedures. Both of them improve function, pain and health
related quality of life (HRQoL). The aim of this study was to
compare baseline scores and improvements at one year inHRQoL
according to the operated joint. METHODS: This prospective
observational study was carried out in 15 hospitals with consecu-
tive patients. All included patients fulﬁlled 3 HRQoL question-
naires at two times, 1 month pre surgery and 12 months post
surgery. There were 2 generic questionnaires; EQ-5D and SF-12
and one speciﬁc, the WOMAC. We compare the baseline scores
and improvements at one year by mean of Student’s t test.
RESULTS: The analysis was performed over 864 patients who
fulﬁlled the included questionnaires. There were 355 hips and 509
knees. Mean age (mean  s.d.) was not different between hip
(63.5  19.9) and knee (64.3  23.8) patients. At baseline,
patients who were waiting for hip replacement had only worse
score in the function dimension of WOMAC (64.8  16.6 vs
61.1  17.6) (p = 0.002). According to the improvements at one
year, there were statistically signiﬁcant differences in all EQ-5D
and WOMAC dimensions. The patients in the hip group experi-
enced higher improvements in EQ-5D index (p = 0.005), VAS
(p = 0.005), WOMAC pain (p < 0.001), function (p = 0.001) and
stiffness (p < 0.001). There were no statistically differences in the
improvements measured by SF-12. CONCLUSIONS: In the light
of these datawe can conclude that at baseline patients have similar
HRQoL scores, while at 1 year those who have undergone hip
replacement experienced a higher improvement in the affected
dimensions. In addition, the generic questionnaire SF-12 does not
seem to capture the changes in HRQoL in these patients.
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OBJECTIVES: To evaluate the effect of golimumab (GLM) on
self-reported productivity in rheumatoid arthritis (RA) patients.
METHODS:The effect of GLMon self-reported productivity was
evaluated in threemulticenter, randomized, double-blind, placebo
(PBO)-controlled studies in RA patients. Data from patients
receiving GLM or PBO with or without methotrexate (MTX) are
presented. The trials evaluated different patient populations and
included patients naïve to MTX (GO-BEFORE), patients with
active RA despite MTX (GO-FORWARD), and patients previ-
ously treated with anti-TNF-alpha agent(s) (GO-AFTER). GLM
subcutaneous injections of 50 mg or 100 mg were administered
q4wks. Atwks0 and 24, patientswere asked to indicate howmuch
their disease affected their productivity at work, school or at home
in the past 4wks using a 0 (did not affect productivity at all) to 10
(affected productivity very much) VAS scale. A negative mean
change from baseline is an improvement in self-reported produc-
tivity. An ANOVA on van der Waerden normal scores was per-
formed for between-group comparisons. RESULTS: In each of
the trials mean baseline scores for self-reported productivity
were comparable between groups (ranges were 6.3–6.4[GO-
BEFORE] 5.4–5.7[GO-FORWARD], 6.2–6.7[GO-AFTER]). In
GO-FORWARD, the mean(SD) improvements in self-reported
productivity were signiﬁcantly greater in the GLM50 and 100 mg
+ MTX groups compared with PBO + MTX at wk24 (-1.97 
3.12, -2.00  2.53, and -0.45  2.98, respectively, p < 0.001).
In GO-AFTER, the mean(SD) improvements in self-reported
productivity were signiﬁcantly greater in the GLM50 and 100 mg
groups compared with PBO at wk24 (-1.77  2.90, -2.10 
2.92, and -0.52  2.79, respectively, p < 0.001). In GO-
BEFORE, numerical improvements in self-reported productivity
were observed in the GLM 50 and 100 mg + MTX groups
(-2.48  2.94 and -2.90  2.80, respectively); these improve-
ments were not signiﬁcantly different from PBO + MTX
(-2.27  3.02). CONCLUSIONS: In two studies, GLM resulted
in signiﬁcant improvements in self-reported productivity. In the
third trial, GLM resulted in trends towards improvement in
self-reported productivity compared with PBO + MTX.
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OBJECTIVES: To evaluate welfare changes in individuals using
balloon kyphoplasty (BKP) for the treatment of vertebral body
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